ImCOVID Study [COVID-19]
Research type
Research Study
Full title
Impact of cardiometabolic risk factors and medications in the severity of COVID-19 disease: ImCOVID Study
IRAS ID
285577
Contact name
Ajay Gupta
Contact email
Sponsor organisation
Queen Mary University of London
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
There is an urgent need to understand risk factors for COVID-19 outcomes within the UK. While there has been research carried out in this area within the UK, and globally, identifying potential risk factors for COVID-19, it is unclear how these modify risk at population level, and how this risk is influenced by other factors, such as treatments, and ethnicity. Understanding risk factors, including demographic, cardiometabolic risk profiles, and treatments for COVID-19 outcomes is vital for risk stratification to inform public health strategies (e.g. identification of high risk and vulnerable population groups), as well as for resource allocation with regard to interventions. Here, we propose a project to study risk factors for COVID-19 using anonymised data for patients admitted with COVID-19 into the Barts & London NHS Trust during the pandemic. The Bart’s NHS Trust covers an ethnically diverse population, allowing examination of how cardiometabolic risk factors, the use of different medications and other factors, such as socio-economic factors contribute to the elevated severity of COVID-19 observed in certain ethnic groups. In order to facilitate our understanding of risk factors for COVID-19 susceptibility and outcomes, we plan to access linked primary care and secondary care data for patients admitted with COVID-19, through databases collecting routine care data that have been linked previously (https://www.qmul.ac.uk/blizard/ceg/discovery/). The data will only include non-identifiable data on patients, including demographic factors, gender, self-reported ethnicity, where available, lifestyle measures, previous clinical diagnoses, laboratory tests, vaccination records, and prescription data in order to examine the impact of various risk factors on COVID-19 outcomes. Outcomes considered will include ICU admission, multi-organ failure, need for oxygen, ventilatory and other organ (e.g. renal replacement therapy) support. This research will be in the public interest, and will inform public health response and policy on the clinical risk stratification of these patients. \n
REC name
N/A
REC reference
N/A